Risk for hypertension even higher for those receiving left-sided radiation therapy, endocrine therapy
THURSDAY, Jan. 20, 2022 (HealthDay News) — Women with, versus without, a history of breast cancer have a higher incidence of hypertension and diabetes up to 10 years following diagnosis, according to a study published online Jan. 13 in the Journal of Clinical Oncology.
Marilyn L. Kwan, Ph.D., from Kaiser Permanente Northern California in Oakland, and colleagues matched (in a 1:5 ratio) 14,942 women with invasive breast cancer (diagnosed from 2005 to 2013) to noncancer controls based on birth year, race, and ethnicity. Rates of hypertension, diabetes, and dyslipidemia were compared by breast cancer status.
The researchers found that breast cancer cases had higher cumulative incidence rates of hypertension (10.9 versus 8.9 percent) and diabetes (2.1 versus 1.7 percent) after two years compared with controls, with higher diabetes incidence persisting after 10 years (9.3 versus 8.8 percent). Breast cancer cases had a higher risk for diabetes (subdistribution hazard ratios [sHR], 1.16) versus controls. Diabetes risk continued to be higher among cases treated with chemotherapy (sHR, 1.23), left-sided radiation (sHR, 1.29), or endocrine therapy (sHR, 1.23). For cases receiving left-sided radiation (sHR, 1.11) or endocrine therapy (sHR, 1.10), hypertension risk was higher. Higher risk was seen for cases with normal weight (body mass index, <24.9 kg/m2) both overall and within treatment subgroups versus controls.
“Study findings highlight patients with breast cancer as a vulnerable population at higher risk of cardiometabolic risk factors and support targeted cardiovascular surveillance by specific patient and treatment characteristics to mitigate these risks,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
Aircrew Face Higher Odds of Radiation-Related Cancer Deaths
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease